Navigation Links
Anakinra for rheumatoid arthritis: A modest benefit with some risk
Date:1/20/2009

New research supports a modest beneficial effect of anakinra for rheumatoid arthritis patients, but warns against potential risks for serious infections and its use with other biologic medications.

Rheumatoid arthritis is a chronic inflammatory disease affecting as many as one in 100 people worldwide. It affects the joints, making them stiff and painful. Anakinra is one of a new breed of arthritis drugs licensed in the past decade called 'biologics'. The drug is the first to target the immune protein IL-1, thought to be partly responsible for inflammation in arthritis patients. It is given by daily injection.

In a Cochrane Systematic Review of five recent anakinra trials involving 2,876 patients, researchers found anakinra reduced pain and stiffness in patients, and helped to improve joint function, when compared to placebo. However, while around a quarter of patients experienced improvement in their symptoms as a result of taking anakinra, the researchers say the improvements are notably less than those seen with other biologics.

In addition, there were more injection site reactions with the use of anakinra and the rate of serious infections with anakinra was approaching statistical significance when compared to placebo. "We would recommend caution with the use of anakinra for rheumatoid arthritis, especially with the only modest beneficial outcomes compared to other biologic medications studied for rheumatoid arthritis," said lead researcher Dr. Marty Mertens of the University of Minnesota in the US.

One study included in the review investigated the combination of anakinra with another biologic medication, etanercept. This found no benefits in arthritis outcomes, but did show a significant increase in the number of serious adverse events. "On the basis of these results, we recommend that doctors avoid combining biologic medications with anakinra when treating patients with rheumatoid arthritis,' said Mertens.

Dr. Mertens thinks more research is required to better inform patients and doctors about the safety of the drug: "We have only limited data on the safety of anakinra, and need more long-term studies to evaluate this, especially the potential for increased risk of serious infections."


'/>"/>

Contact: Jennifer Beal
wbnewseurope@wiley.com
44-012-437-70633
Wiley-Blackwell
Source:Eurekalert

Related biology news :

1. Study identifies genetic risk factor for rheumatoid arthritis, lupus
2. New Actemra data shows significant benefit for patients suffering from rheumatoid arthritis
3. Blood clotting protein linked to rheumatoid arthritis
4. Electronic switch opens doors in rheumatoid joints
5. New guidelines for treating rheumatoid arthritis
6. New therapeutic target identified for rheumatoid arthritis
7. Anything but modest: The mouse continues to contribute to humankind
8. Modest CO2 cutbacks may be too little, too late for coral reefs
9. Tufts University biologists link Huntingtons disease to health benefits in young
10. The benefits of 80 million years without sex
11. New data shows benefits of MitraClip for patients with mitral regurgitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... BLOOMINGTON, Ill. , Oct. 4, 2017  GCE Solutions, a ... powerful new data and document anonymization solution on October 4, 2017. ... the pharmaceutical field to comply with policy 0070 of the European ... documents and data. ... Innovation by GCE Solutions ...
(Date:6/23/2017)... and ITHACA, N.Y. , ... and Cornell University, a leader in dairy research, today ... bioinformatics designed to help reduce the chances that the ... the onset of this dairy project, Cornell University has ... for Sequencing the Food Supply Chain, a food safety ...
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... SANTA BARBARA, CALIFORNIA (PRWEB) , ... October 10, ... ... risk management, technological innovation and business process optimization firm for the life sciences ... the BoxWorks conference in San Francisco. , The presentation, “Automating GxP ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness ... targeting the needs of consumers who are incorporating medical marijuana into their wellness ... Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s two ...
(Date:10/6/2017)... ... October 06, 2017 , ... The ... and technology sector at their fourth annual Conference where founders, investors, innovative practitioners ... and the ELEVATE pitch competition showcasing early stage digital health and med tech ...
Breaking Biology Technology: